Dermapharm Holding SE

Total Valuation

Dermapharm Holding SE carries a market capitalization of 2.36B, placing it among publicly traded companies globally. Its enterprise value stands at 3.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Dermapharm Holding SE currently has 49.54M shares outstanding.

Valuation Ratios

Dermapharm Holding SE trades at a trailing price-to-earnings ratio of 16.34. The price-to-sales ratio is 2.03, and the price-to-book ratio stands at 4.28.

Enterprise Valuation

On an enterprise value basis, Dermapharm Holding SE trades at an EV/EBITDA multiple of 12.24 and an EV/FCF ratio of 9.29. The EV/Sales ratio of 2.74 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.24 provides insight into valuation relative to core operating earnings.

Financial Position

Dermapharm Holding SE maintains a current ratio of 1.71, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 219.34, indicating elevated leverage, while an interest coverage ratio of 5.56 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Dermapharm Holding SE posts a return on equity of 25.60 and a return on invested capital of 11.83.

Taxes

Over the trailing twelve months, Dermapharm Holding SE has paid 47.23M in income taxes, reflecting an effective tax rate of 24.50.

Stock Price Statistics

Dermapharm Holding SE's stock has gained approximately 20.55106% over the past 52 weeks. The 50-day moving average sits at 49.39, while the 200-day moving average is 42.35.

Income Statement

Over the trailing twelve months, Dermapharm Holding SE generated 1.18B in revenue and converted that into 146.54M in net income, yielding earnings per share of 2.82. EBITDA reached 264.75M, while operating income came in at 264.75M.

Balance Sheet

Dermapharm Holding SE holds 223.58M in cash and equivalents against 1.17B in total debt, resulting in a net debt position of 949.89M. Total book value stands at 536.71M, with working capital of 317.61M providing operational flexibility.

Cash Flow

Dermapharm Holding SE produced 264.34M in operating cash flow over the past twelve months. After subtracting -48.39M in capital expenditures, free cash flow totaled 215.96M - equivalent to 4.18 per share.

Margins

Dermapharm Holding SE operates with a gross margin of 68.14, reflecting its pricing power and cost economics. The operating margin of 22.41 and net profit margin of 12.40 provide insight into operational efficiency.

Dividends & Yields

Scores

Dermapharm Holding SE posts an Altman Z-Score of 3.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.